Lorlatinib induced proteinuria: A case report.
ALK
Lorlatinib
ROS1
non-small cell lung cancer
proteinuria
Journal
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
pubmed:
1
10
2020
medline:
22
6
2021
entrez:
30
9
2020
Statut:
ppublish
Résumé
Lorlatinib is an oral anaplastic lymphoma kinase (ALK) and C-ros oncogene (ROS1) tyrosine kinase inhibitor with excellent central nervous system (CNS) penetrability. It is currently approved for use as second line therapy for those with ALK positive non-small cell lung cancer (NSCLC). Given its CNS penetrating effects, lorlatinib has shown to cause CNS adverse events such as seizures, hallucinations, and changes in cognitive function. To our knowledge proteinuria has not been previously described with this medication. We report a case lorlatinib induced proteinuria in a patient receiving lorlatinib as second line treatment for ROS1 rearranged NSCLC. Our case demonstrates objective evidence for proteinuria induced by lorlatinib, which may also be dose dependent.
Identifiants
pubmed: 32996364
doi: 10.1177/1078155220961549
doi:
Substances chimiques
Aminopyridines
0
Lactams
0
Lactams, Macrocyclic
0
Protein Kinase Inhibitors
0
Pyrazoles
0
lorlatinib
OSP71S83EU
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM